Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvamibe vs Rosuvastatin in High ASCVD Risk T2D Patients
NCT03403556Phase 4Unknown
- Sponsor
- Yuhan
- Start
- Mar 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ezetimibe + rosuvastatin in hypercholesterolemia, atherosclerotic cardiovascular disease (ASCVD), sponsored by Yuhan. Status: unknown.
02
Drugs
ezetimibe + rosuvastatin
03
Conditions
hypercholesterolemiaatherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT03403556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03403556.